<DOC>
	<DOCNO>NCT00854204</DOCNO>
	<brief_summary>The purpose study compare bioavailability ( degree drug become available body administration ) 3 different pharmaceutical preparation combination two drug , TMC114 TMC41629 . There 1 single oral intake ( intake mouth ) 3 preparation . The study also investigate safety use potential side effect TMC114 TMC41629 , determine circulating level compound blood time ( pharmacokinetics ) , single intake .</brief_summary>
	<brief_title>Innovation-TiFP4-C101 : A Study Evaluate Pharmacokinetics TMC114 TMC41629 After Single Oral Dose 2 Controlled-release Coformulations Compared Immediate-release Coformulation TMC114/TMC41629</brief_title>
	<detailed_description>TMC41629 new investigational drug treatment HIV . TMC114 , also know Darunavir . In randomized ( study medication assign chance ) , open label trial ( investigator healthy volunteer know name study medication ) , healthy volunteer receive single dose TMC114/TMC41629 , 3 subsequent session , Treatment A , Treatment B Treatment C. Each capsule equivalent dose 200 mg TMC114 23.67 mg TMC41629 . Treatment A ( immediate-release formulation ) serve reference formulation . All medication intake orally fast conditions.The study duration least 19 day , exclude screen follow-up visit three single intake 72 hour follow-up per intake . Each volunteer receive single dose formulation . TMC114/TMC41629 formulate oral immediate-release hard-gelatin capsule , oral gastro-resistant hard-gelatin capsule , enteric-coated oral gastro-resistant hard-gelatin capsule , colon-targeted . Each capsule equivalent dose 200 mg TMC114 23.67 mg TMC41629 .</detailed_description>
	<mesh_term>Darunavir</mesh_term>
	<criteria>Nonsmoking least 3 month prior selection Normal weight define Body Mass Index ( BMI , weight kg divide square height meter ) 18.0 30.0 kg/m2 , extremes include Informed Consent Form ( ICF ) sign voluntarily first trialrelated activity Able comply protocol requirement Healthy basis medical evaluation confirms absence clinically relevant abnormality include physical examination , medical history , result blood biochemistry , coagulation , hematology test , urinalysis , vital sign , 12lead electrocardiogram ( ECG ) ( triplicate ) follow parameter carry screening : a. heart rate ( HR ) 40 100 bpm b. QTc interval = 450 m c. QRS interval low 120 m d. PR interval = 220 ms. Past history heart arrhythmias History evidence current use alcohol , barbiturate , amphetamine , recreational narcotic drug use , investigator 's opinion would compromise subject 's safety and/or compliance trial procedure Hepatitis A , B , C infection HIV1 HIV2 infection screen Currently active underlie gastrointestinal , cardiovascular , neurologic , psychiatric , metabolic , endocrinologic , genitourinary , renal , hepatic , respiratory , inflammatory , infectious disease Any history significant skin disease allergy drug</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Innovation-TiFP4-C101</keyword>
	<keyword>Innovation-C101</keyword>
	<keyword>Innovation</keyword>
	<keyword>TMC114/TMC41629</keyword>
	<keyword>controlled-release coformulations</keyword>
	<keyword>immediate-release coformulation</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>